Summary by Futu AI
Altimmune, Inc.'s Chief Scientific Officer, M Scot Roberts, completed a series of transactions involving the company's common stock on February 1 and 2, 2024. Roberts acquired a total of 13,941 shares through the exercise of derivative securities at no cost. Concurrently, Roberts disposed of 4,131 shares to cover exercise prices or tax liabilities, with the transactions priced between $9.32 and $9.88 per share, resulting in a total market value of $39,509.48. Following these transactions, Roberts directly holds 42,660 shares of Altimmune. Additionally, an indirect holding of 15 shares is reported, owned by the spouse of the reporting person.